2.

乳腺浸润性导管癌组织JMJD3、MMP-2和VEGF表达与临床病理特征的关系

Association of JMJD3, MMP-2, and VEGF expression with clinicopathological characteristics of breast cancer (Mean±SD)

Characteristics	n	JMJD3			MMP-2			VEGF
		PU	P		PU	P		PU	P
a1, a2, a3, b1, b2, b3, c1, c2, c3, c4P < 0.05 vs the corresponding group, respectively.
Age (year)
≥50	50	14.52±5.20	0.225		14.10±4.78	0.779		14.04±4.70	0.933
< 50	55	12.54±5.17			13.81±5.80			14.12±5.66
Position
Left	49	13.95±4.89	0.579	13.33±5.25	0.268	13.58±5.44	0.363
Right	56	13.37±5.64		14.49±5.36		14.52±5.00
Maximal tumor diameter(cm)
≤2	35	17.15±4.64a2, a3	0.000		12.71±5.56a3	0.005		13.34±6.00a3	0.013
> 2, ≤5	40	13.30±3.52a1, a3			13.07±4.48a3			12.98±4.04a3
> 5	30	10.01±5.44a1, a2			16.57±5.29a1, a2			16.41±5.00a1, a2
Histologic differentiation
Well differentiation	38	16.93±4.54b2, b3	0.000		12.80±5.45b3	0.006		13.38±5.85b3	0.016
Moderate differentiation	39	13.18±3.66b1, b3			13.15±4.51b3			13.05±4.06b3
Poor differentiation	28	9.82±5.45b1, b2			16.63±5.41b1, b2			16.46±5.12b1, b2
Lymph node metastasis
Without	57	16.43±3.90	0.000		13.12±5.16	0.010		12.72±4.97	0.038
With	48	10.33±4.81			15.22±5.07			15.41±5.39
TNM stage
Ⅰ+Ⅱ	54	14.93±4.27	0.010		11.52±4.38	0.000		11.88±4.57	0.000
Ⅲ+Ⅳ	51	12.28±5.93			16.52±5.03			16.41±4.84
Molecular subtypes
Luminal A	44	16.64±5.17c3, c4	0.000		11.63±4.92c2, c3	0.000		12.07±5.25c2, c3	0.002
Luminal B	36	14.14±3.94c3, c4			16.13±5.2c1, c4			16.12±4.88c1, c4
Her-2 overexpression	15	8.17±3.28c1, c2			16.01±4.53c1, c4			15.73±4.62c1, c4
Basal like pattern	10	9.35±3.09c1, c2			12.63±4.66c2, c3			12.69±4.12c2, c3